Nrf2 Activator Program
Parkinson's Disease
Key Facts
About Keapstone Therapeutics
Keapstone Therapeutics is a private, preclinical-stage biotech founded in 2021, originating from the Sheffield Institute for Translational Neuroscience. The company is pioneering a unique approach to neuroprotection by developing small molecules that activate the Nrf2 pathway, aiming to simultaneously improve redox balance, mitochondrial function, autophagy, and reduce inflammation. With strong academic roots and backing from Parkinson's UK, Keapstone is advancing its platform towards treatments for neurodegenerative diseases with high unmet need, though it faces significant development and competitive risks inherent to CNS drug discovery.
View full company profileAbout Keapstone Therapeutics
Keapstone Therapeutics is a private, preclinical-stage biotech founded in 2021, originating from the Sheffield Institute for Translational Neuroscience. The company is pioneering a unique approach to neuroprotection by developing small molecules that activate the Nrf2 pathway, aiming to simultaneously improve redox balance, mitochondrial function, autophagy, and reduce inflammation. With strong academic roots and backing from Parkinson's UK, Keapstone is advancing its platform towards treatments for neurodegenerative diseases with high unmet need, though it faces significant development and competitive risks inherent to CNS drug discovery.
View full company profileOther Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |